Tumor necrosis factor receptor superfamily member 11A (RANK) (RANK)

Tumor necrosis factor receptor superfamily member 11A, commonly known as RANK (Receptor Activator of Nuclear Factor kappa-B), is a type I transmembrane protein that serves as the primary signaling receptor for the cytokine RANKL (TNFSF11). It is predominantly expressed on osteoclast precursors, mature osteoclasts, and dendritic cells, where it plays a master regulatory role in the differentiation, activation, and survival of bone-resorbing cells. The RANK/RANKL/OPG signaling axis is critical for maintaining skeletal homeostasis; disruptions in this balance lead to metabolic bone diseases such as osteoporosis, Paget's disease, and bone metastasis. Beyond its skeletal functions, RANK is essential for immune system regulation, particularly in the interaction between T cells and dendritic cells, as well as for lymph node organogenesis and mammary gland development. In clinical practice, the RANK pathway is a major therapeutic target, most notably for the monoclonal antibody denosumab, which neutralizes RANKL to prevent receptor activation and inhibit pathological bone loss. The target name 'TNFRSF11' is considered incomplete as it lacks the specific suffix (A or B) required to distinguish between the signaling receptor (RANK) and its decoy receptor (Osteoprotegerin).

Other names

TNFRSF11ACD265Receptor activator of nuclear factor kappa-BTRANCE receptorOsteoclast differentiation factor receptor (ODFR)NFKB activatorLOH18CR1PDB2

RANKL (TNFSF11) binds to the RANK receptor, triggering the recruitment of TRAF6 and activation of NF-kappaB and MAPK signaling pathways to drive osteoclastogenesis. Therapeutic agents like Denosumab inhibit this pathway by binding and neutralizing the ligand (RANKL), thereby preventing receptor activation and subsequent bone resorption.